New Targeted Therapy Earns Cancer Designations
Adults with advanced colorectal or lung cancer may benefit from this experimental drug's faster review pathway, though it remains investigational.
Updated on Nov. 3, 2026 in Cancer
The U.S. Food and Drug Administration granted two Breakthrough Therapy Designations to AbbVie's telisotuzumab adizutecan (Temab-A), an experimental antibody-drug conjugate. One covers use with bevacizumab in adults with refractory metastatic colorectal cancer, and the other covers standalone use in certain adults with non-small cell lung cancer.
Why it matters
Colorectal and lung cancers remain major causes of cancer-related deaths worldwide, and patients whose disease has stopped responding to standard treatments have limited options. The designation is meant to speed development and review of investigational medicines for serious conditions, so the decision signals regulatory confidence in early clinical results.
The designations rest mainly on the first-in-human M21-404 trial, an early-phase study in adults with advanced solid tumours. Preliminary clinical evidence suggests the therapy may offer substantial improvement over available treatments, but the specific effect sizes are not part of this announcement.
The players
AbbVie
A global biopharmaceutical company with major treatment areas in oncology, immunology, and neuroscience, and the developer of Temab-A.
U.S. Food and Drug Administration
The federal agency responsible for approving and regulating drugs and biologics in the United States, including its Breakthrough Therapy Designation program for serious conditions.
The details
Temab-A is a next-generation antibody-drug conjugate designed to target the c-Met protein, which appears at elevated levels in several solid tumours. It pairs a humanised monoclonal antibody that binds c-Met with a topoisomerase I inhibitor payload. The design aims to deliver the cell-damaging drug directly to target cells while limiting its release into the wider body.
Timeline
Announcement of the Temab-A Breakthrough Therapy Designations was published on November 3, 2026.
Health Landscape
The FDA's Breakthrough Therapy Designation program is intended to accelerate development of drugs for serious conditions where early evidence suggests substantial improvement over existing options. Temab-A's designations place a targeted antibody-drug conjugate within that pathway for colorectal and lung cancers, two areas where treatment options for later-stage disease remain limited.
If you or a family member has been diagnosed with metastatic colorectal or non-small cell lung cancer and has already tried standard treatments, this is worth raising with your oncologist, who can tell you whether clinical trials involving investigational therapies may be an option. Designations like this do not mean the drug is available, so the practical step today is a conversation with your care team rather than any change in treatment.
The takeaway
Breakthrough Therapy Designation reflects early promise, not proven benefit, so results from later-stage trials will determine whether Temab-A reaches patients. For people managing advanced colorectal or lung cancer, asking your oncologist about current clinical trial options is a practical step to take.
Further reading
For broader context on how new therapies move through review, explore our Cancer coverage.
